Compare RF & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RF | UTHR |
|---|---|---|
| Founded | 1970 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 20.5B |
| IPO Year | N/A | 1999 |
| Metric | RF | UTHR |
|---|---|---|
| Price | $30.79 | $473.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | $29.10 | ★ $498.83 |
| AVG Volume (30 Days) | ★ 15.9M | 329.5K |
| Earning Date | 01-16-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 19.17 | 16.08 |
| EPS | 2.30 | ★ 26.38 |
| Revenue | ★ $7,056,000,000.00 | $3,128,400,000.00 |
| Revenue This Year | $15.12 | $13.57 |
| Revenue Next Year | $3.78 | $5.72 |
| P/E Ratio | ★ $13.40 | $17.94 |
| Revenue Growth | 6.97 | ★ 13.50 |
| 52 Week Low | $17.74 | $266.98 |
| 52 Week High | $31.17 | $519.99 |
| Indicator | RF | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 69.71 | 46.17 |
| Support Level | $27.59 | $462.02 |
| Resistance Level | $31.16 | $489.50 |
| Average True Range (ATR) | 0.64 | 9.60 |
| MACD | 0.24 | 0.93 |
| Stochastic Oscillator | 90.28 | 41.99 |
Regions Financial is one of the midsized regional banks in the US, with around $160 billion in total assets as of Sept. 30, 2025. Headquartered in Birmingham, Alabama, Regions Financial has a footprint mostly in the US southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, wealth management, and capital markets.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.